260,000 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Acquired by B Group Inc.

B Group Inc. purchased a new position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 260,000 shares of the company's stock, valued at approximately $7,233,000. Akero Therapeutics accounts for 4.4% of B Group Inc.'s holdings, making the stock its 6th largest position. B Group Inc. owned approximately 0.37% of Akero Therapeutics as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Sterling Capital Management LLC increased its position in Akero Therapeutics by 764.3% during the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock worth $50,000 after acquiring an additional 1,582 shares during the period. Summit Investment Advisors Inc. increased its holdings in shares of Akero Therapeutics by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company's stock worth $197,000 after purchasing an additional 450 shares during the period. AlphaQuest LLC raised its position in shares of Akero Therapeutics by 32,588.0% during the fourth quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock valued at $227,000 after buying an additional 8,147 shares during the last quarter. Optimize Financial Inc bought a new stake in shares of Akero Therapeutics in the fourth quarter valued at about $232,000. Finally, Sei Investments Co. bought a new stake in shares of Akero Therapeutics in the fourth quarter valued at about $303,000.

Insiders Place Their Bets

In other Akero Therapeutics news, CEO Andrew Cheng sold 30,000 shares of the stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $35.23, for a total value of $1,056,900.00. Following the transaction, the chief executive officer now directly owns 624,324 shares in the company, valued at approximately $21,994,934.52. This trade represents a 4.58 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director G. Walmsley Graham bought 200,000 shares of the company's stock in a transaction dated Thursday, January 30th. The shares were purchased at an average price of $48.00 per share, with a total value of $9,600,000.00. Following the transaction, the director now owns 1,000,000 shares of the company's stock, valued at $48,000,000. The trade was a 25.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 341,309 shares of company stock valued at $15,863,578 and sold 287,458 shares valued at $13,689,886. Insiders own 7.94% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on AKRO shares. Citigroup upped their price target on Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. UBS Group upped their target price on Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a research note on Friday, January 31st. Bank of America raised Akero Therapeutics from a "neutral" rating to a "buy" rating and raised their target price for the stock from $35.00 to $63.00 in a research report on Thursday, January 30th. Canaccord Genuity Group boosted their price target on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $76.29.

Akero Therapeutics Price Performance

Shares of NASDAQ:AKRO traded up $0.01 during trading on Friday, reaching $41.00. The stock had a trading volume of 959,240 shares, compared to its average volume of 865,646. The stock has a market capitalization of $3.26 billion, a PE ratio of -10.93 and a beta of -0.18. Akero Therapeutics, Inc. has a 52 week low of $17.86 and a 52 week high of $58.40. The business's 50-day moving average price is $42.24 and its 200 day moving average price is $36.52. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its earnings results on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). As a group, equities analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.